New drug combo aims to shield Kids' kidneys from rare disease
NCT ID NCT07315191
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether adding finerenone to standard blood pressure medication (ACEI/ARB) can better reduce protein in the urine of children with Henoch-Schönlein purpura nephritis and mild proteinuria. About 116 children aged 3 to 17 will take either finerenone plus ACEI/ARB or ACEI/ARB alone for 3 months. The goal is to see if the combination lowers kidney damage risk without serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- finerenone
- What this could lead to
- If it works, this could point toward a better treatment for children with mild kidney inflammation from Henoch-Schönlein purpura, potentially slowing or preventing kidney disease progression.
- What could go wrong
- This is a small, early-phase trial with only 116 children, so results may not apply to all patients. Finerenone may not reduce proteinuria more than standard care, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HENOCH SCHÖNLEIN PURPURA NEPHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Capital Center for Children's Health,Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100020, China